Chromatin targeting drugs in cancer and immunity

Genes and Development

Volumn 27, Issue 16, 2013, Pages 1731-1738

  Prinjha, Rab ^a   Tarakhovsky, Alexander ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cancer; Chromatin; Immunity

Indexed keywords

HISTONE METHYLTRANSFERASE;

CANCER THERAPY; CELL DIFFERENTIATION; CELL FUNCTION; CHROMATIN; DNA MODIFICATION; ENZYMOLOGY; GENE CONTROL; HUMAN; IMMUNITY; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

CANCER; CHROMATIN; IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATIN; HUMANS; IMMUNITY; IMMUNOMODULATION; NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTORS;

EID: 84882604941     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.221895.113     Document Type: Review

References (117)

1. Abbas A.K., Janeway CA Jr. 2000. Immunology: Improving on nature in the twenty-first century. Cell 100: 129-138.
2. Arrowsmith C.H., Bountra C, Fish PV, Lee K, Schapira M. 2012. Epigenetic protein families: A new frontier for drug discovery. Nat Rev Drug Discov 11: 384-400.
3. Bandukwala H.S., Gagnon J, Togher S, Greenbaum JA, Lamperti ED, Parr NJ, MolesworthAM, Smithers N, LeeK, Witherington J, et al. 2012. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc Natl Acad Sci 109: 14532-14537.
4. Bannister A.J., Kouzarides T. 2011. Regulation of chromatin by histone modifications. Cell Res 21: 381-395.
5. Belkina A.C., Denis GV. 2012. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 12: 465-477.
6. Belkina A.C., Nikolajczyk BS, Denis GV. 2013. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol 190: 3670-3678.
7. Bezbradica J.S., Medzhitov R. 2009. Integration of cytokine and heterologous receptor signaling pathways. Nat Immunol 10: 333-339.
8. Bhatt D.M., Pandya-Jones A, Tong AJ, Barozzi I, Lissner MM, Natoli G., Black DL, Smale ST. 2012. Transcript dynamics of proinflammatory genes revealed by sequence analysis of subcellular RNA fractions. Cell 150: 279-290.
9. Bierne H., Hamon M, Cossart P. 2012. Epigenetics and bacterial infections. Cold Spring Harb Perspect Med 2: a010272.
10. Bisgrove D.A., Mahmoudi T, Henklein P, Verdin E. 2007. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci 104: 13690-13695.
11. Bryant R.J., Winder SJ, Cross SS, Hamdy FC, Cunliffe VT. 2008. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells. Prostate 68: 255-263.
12. Busslinger M. 2004. Transcriptional control of early B cell development. Annu Rev Immunol 22: 55-79.
13. Cao R., Zhang Y. 2004. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 15: 57-67.
14. Cao R., Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. 2002. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298: 1039-1043.
15. Chan K.M., Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N., Mueller S, James CD, Jenkins R, et al. 2013. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27: 985-990.
16. Cheung W.L., Briggs SD, Allis CD. 2000. Acetylation and chromosomal functions. Curr Opin Cell Biol 12: 326-333.
17. Crowley T., Brunori M, Rhee K, Wang X, Wolgemuth DJ. 2004. Change in nuclear-cytoplasmic localization of a double-bromodomain protein during proliferation and differentiation of mouse spinal cord and dorsal root ganglia. Brain Res Dev Brain Res 149: 93-101.
18. Cuddapah S., Barski A, Zhao K. 2010. Epigenomics of T cell activation, differentiation, and memory. Curr Opin Immunol 22: 341-347.
19. Czermin B., Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. 2002. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111: 185-196.
20. Dang CV. 2012. MYC on the path to cancer. Cell 149: 22-35.
21. Dawson M.A., Kouzarides T. 2012. Cancer epigenetics: From mechanism to therapy. Cell 150: 12-27.
22. Dawson M.A., Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, et al. 2011. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478: 529-533.
23. Delmore J.E., Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E., Gilpatrick T, Paranal RM, Qi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
24. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. 2007. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 130: 1083-1094.
25. Dey A., Chitsaz F, Abbasi A, Misteli T, Ozato K. 2003. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci 100: 8758-8763.
26. Donlin L.T., Andresen C, Just S, Rudensky E, Pappas CT, Kruger M, Jacobs EY, Unger A, Zieseniss A, Dobenecker MW, et al. 2012. Smyd2 controls cytoplasmic lysinemethylation of Hsp90 and myofilament organization. Genes Dev 26: 114-119.
27. Ebert A., McManus S, Tagoh H, Medvedovic J, Salvagiotto G, Novatchkova M., Tamir I, Sommer A, Jaritz M, Busslinger M. 2011. The distal V(H) gene cluster of the Igh locus contains distinct regulatory elements with Pax5 transcription factordependent activity in pro-B cells. Immunity 34: 175-187.
28. Ernst T., Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, et al. 2010. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722-726.
29. Fang T.C., Schaefer U, Mecklenbrauker I, Stienen A, Dewell S, Chen M.S., Rioja I, Parravicini V, Prinjha RK, Chandwani R, et al. 2012. Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J Exp Med 209: 661-669.
30. Ferrari R., Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK. 2008. Epigenetic reprogramming by adenovirus e1a. Science 321: 1086-1088.
31. Filippakopoulos P., Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse E.M., Keates T, Hickman TT, Felletar I, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
32. Fonseca G.J., Thillainadesan G, Yousef AF, Ablack JN, Mossman KL, Torchia J, Mymryk JS. 2012. Adenovirus evasion of interferon-mediated innate immunity by direct antagonism of a cellular histone posttranslational modification. Cell Host Microbe 11: 597-606.
33. Gonzalez M.E., DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, Kleer CG. 2011. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res 71: 2360-2370.
34. Guglielmelli P., Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, et al. 2011. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 118: 5227-5234.
35. Guo N., Faller DV, Denis GV. 2000. Activation-induced nuclear translocation of RING3. J Cell Sci 113: 3085-3091.
36. Hargreaves D.C., Horng T, Medzhitov R. 2009. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138: 129-145.
37. He S., Wang J, Kato K, Xie F, Varambally S, Mineishi S, Kuick R, Mochizuki K., Liu Y, Nieves E, et al. 2012. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood 119: 1274-1282.
38. Hobert O., Jallal B, Ullrich A. 1996a. Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. Mol Cell Biol 16: 3066-3073.
39. Hobert O., Schilling JW, Beckerle MC, Ullrich A, Jallal B. 1996b. SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin. Oncogene 12: 1577-1581.
40. Huang B., Yang XD, Zhou MM, Ozato K, Chen LF. 2009. Brd4 coactivates transcriptional activation of NF-kB via specific binding to acetylated RelA. Mol Cell Biol 29: 1375-1387.
41. Iwasaki A., Medzhitov R. 2010. Regulation of adaptive immunity by the innate immune system. Science 327: 291-295.
42. Jacob E., Hod-Dvorai R, Schif-Zuck S, Avni O. 2008. Unconventional association of the polycomb group proteins with cytokine genes in differentiated T helper cells. J Biol Chem 283: 13471-13481.
43. Jacob E., Hod-Dvorai R, Ben-Mordechai OL, Boyko Y, Avni O. 2011. Dual function of polycomb group proteins in differentiated murine T helper (CD4+) cells. J Mol Signal 6: 5.
44. Jankowska A.M., Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F., Visconte V, Sugimoto Y, Prince C, O'Keefe C, et al. 2011. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118: 3932-3941.
45. Jenuwein T., Allis CD. 2001. Translating the histone code. Science 293: 1074-1080.
46. Jiang Y.W., Veschambre P, Erdjument-Bromage H, Tempst P, Conaway J.W., Conaway RC, Kornberg RD. 1998. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc Natl Acad Sci 95: 8538-8543.
47. Kim M.Y., Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L., Massague J. 2009. Tumor self-seeding by circulating cancer cells. Cell 139: 1315-1326.
48. Kim J., GuermahM, Roeder RG. 2010. The human PAF1 complex acts in chromatin transcription elongation both independently and cooperatively with SII/TFIIS. Cell 140: 491-503.
49. Kleer C.G., Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D., Sewalt RG, Otte AP, Hayes DF, et al. 2003. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci 100: 11606-11611.
50. Kouzarides T. 2007. Chromatin modifications and their function. Cell 128: 693-705.
51. Krogan N.J., Dover J, Wood A, Schneider J, Heidt J, Boateng MA, Dean K., Ryan OW, Golshani A, Johnston M, et al. 2003. The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: Linking transcriptional elongation to histone methylation. Mol Cell 11: 721-729.
52. Kruidenier L., Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M., Bountra C, Bridges A, Diallo H, et al. 2012. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488: 404-408.
53. Lamonica J.M., DengW, Kadauke S, Campbell AE, Gamsjaeger R, Wang H., Cheng Y, Billin AN, Hardison RC, Mackay JP, et al. 2011. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc Natl Acad Sci 108: E159-E168.
54. Landeira D., Sauer S, Poot R, Dvorkina M, Mazzarella L, Jorgensen H.F., Pereira CF, Leleu M, Piccolo FM, Spivakov M, et al. 2010. Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA polymerase II to developmental regulators. Nat Cell Biol 12: 618-624.
55. Lee J.S., Kim Y, Kim IS, Kim B, Choi HJ, Lee JM, Shin HJ, Kim JH, Kim J.Y., Seo SB, et al. 2010. Negative regulation of hypoxic responses via induced Reptin methylation. Mol Cell 39: 71-85.
56. Lee J.M., Lee JS, Kim H, Kim K, Park H, Kim JY, Lee SH, Kim IS, Kim J., Lee M, et al. 2012. EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol Cell 48: 572-586.
57. Lewis P.W., Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD. 2013. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340: 857-861.
58. Li G., Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D. 2010. Jarid2 and PRC2, partners in regulating gene expression. Genes Dev 24: 368-380.
59. Loven J., Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner J.E., Lee TI, Young RA. 2013. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153: 320-334.
60. Malin S., McManus S, Cobaleda C, Novatchkova M, Delogu A, Bouillet P., Strasser A, Busslinger M. 2010. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol 11: 171-179.
61. Mandal M., Powers SE, Maienschein-Cline M, Bartom ET, Hamel K.M., Kee BL, Dinner AR, Clark MR. 2011. Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2. Nat Immunol 12: 1212-1220.
62. Marazzi I., Ho JS, Kim J, Manicassamy B, Dewell S, Albrecht RA, Seibert C.W., Schaefer U, Jeffrey KL, Prinjha RK, et al. 2012. Suppression of the antiviral response by an influenza histone mimic. Nature 483: 428-433.
63. Margueron R., Reinberg D. 2011. The Polycomb complex PRC2 and its mark in life. Nature 469: 343-349.
64. Martinez-Garcia E, Licht JD. 2010. Deregulation of H3K27 methylation in cancer. Nat Genet 42: 100-101.
65. Maruyama T., Farina A, Dey A, Cheong J, Bermudez VP, Tamura T, Sciortino S, Shuman J, Hurwitz J, Ozato K. 2002. A Mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase. Mol Cell Biol 22: 6509-6520.
66. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller G.S., Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, et al. 2012. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108-112.
67. Medzhitov R. 2001. Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145.
68. Medzhitov R. 2008. Origin and physiological roles of inflammation. Nature 454: 428-435.
69. Medzhitov R., Janeway CA Jr. 1997. Innate immunity: The virtues of a nonclonal system of recognition. Cell 91: 295-298.
70. Mellman I., Coukos G, Dranoff G. 2011. Cancer immunotherapy comes of age. Nature 480: 480-489.
71. Melnick A. 2012. Epigenetic therapy leaps ahead with specific targeting of EZH2. Cancer Cell 22: 569-570.
72. Meylan E., Tschopp J, Karin M. 2006. Intracellular pattern recognition receptors in the host response. Nature 442: 39-44.
73. Morin R.D., Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et al. 2010. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42: 181-185.
74. Mousavi K., Zare H, Wang AH, Sartorelli V. 2012. Polycomb protein Ezh1 promotes RNA polymerase II elongation. Mol Cell 45: 255-262.
75. Mujtaba S., Zeng L, Zhou MM. 2007. Structure and acetyl-lysine recognition of the bromodomain. Oncogene 26: 5521-5527.
76. Naito T., Tanaka H, Naoe Y, Taniuchi I. 2011. Transcriptional control of T-cell development. Int Immunol 23: 661-668.
77. Natoli G., Ghisletti S, Barozzi I. 2011. The genomic landscapes of inflammation. Genes Dev 25: 101-106.
78. Nicodeme E., Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, et al. 2010. Suppression of inflammation by a synthetic histone mimic. Nature 468: 1119-1123.
79. Nolz J.C., Gomez TS, Billadeau DD. 2005. The Ezh2 methyltransferase complex: Actin up in the cytosol. Trends Cell Biol 15: 514-517.
80. Ntziachristos P., Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, da Ros V, Tang Z, Siegle J, et al. 2012. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 18: 298-301.
81. Ogawa M., Hiraoka Y, Aiso S. 2003. The Polycomb-group protein ENX-2 interacts with ZAP-70. Immunol Lett 86: 57-61.
82. Ott C.J., Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung A.L., Bradner JE, Weinstock DM. 2012. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120: 2843-2852.
83. Palm N.W., Medzhitov R. 2009. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227: 221-233.
84. Pasare C., Medzhitov R. 2005. Toll-like receptors: Linking innate and adaptive immunity. Adv Exp Med Biol 560: 11-18.
85. Pasini D., Bracken AP, Helin K. 2004. Polycomb group proteins in cell cycle progression and cancer. Cell Cycle 3: 396-400.
86. Pasini D., Cloos PA, Walfridsson J, Olsson L, Bukowski JP, Johansen J.V., Bak M, Tommerup N, Rappsilber J, Helin K. 2010. JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature 464: 306-310.
87. Peng J.C., Valouev A, Swigut T, Zhang J, Zhao Y, Sidow A, Wysocka J. 2009. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 139: 1290-1302.
88. Peterlin B.M., Price DH. 2006. Controlling the elongation phase of transcription with P-TEFb. Mol Cell 23: 297-305.
89. Prinjha R.K., Witherington J, Lee K. 2012. Place your BETs: The therapeutic potential of bromodomains. Trends Pharmacol Sci 33: 146-153.
90. Puissant A., Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz E.A., Zeid R, Gustafson WC, Greninger P et al. 2013. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 3: 308-323.
91. Rahman S., Sowa ME, Ottinger M, Smith JA, Shi Y, Harper JW, Howley PM. 2011. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol 31: 2641-2652.
92. Rajewsky K. 1996. Clonal selection and learning in the antibody system. Nature 381: 751-758.
93. Rice AP. 2013. P-TEFb as a target to reactivate latent HIV: Two Brds are now in hand. Cell Cycle 12: 392-393.
94. Ruthenburg A.J., Li H, Patel DJ, Allis CD. 2007. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 8: 983-994.
95. Saccani S., Natoli G. 2002. Dynamic changes in histone H3 Lys 9 methylation occurring at tightly regulated inducible inflammatory genes. Genes Dev 16: 2219-2224.
96. Sampath S.C., Marazzi I, Yap KL, Sampath SC, Krutchinsky AN, Mecklenbrauker I., Viale A, Rudensky E, Zhou MM, Chait BT, et al. 2007. Methylation of a histone mimic within the histone methyltransferase G9a regulates protein complex assembly. Mol Cell 27: 596-608.
97. Schreiber R.D., Old LJ, Smyth MJ. 2011. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
98. Sharma P., Wagner K, Wolchok JD, Allison JP. 2011. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer 11: 805-812.
99. Shaughnessy JD. 2008. Cancer: An unexpected addiction. Nature 454: 172-173.
100. Smale ST. 2012. Transcriptional regulation in the innate immune system. Curr Opin Immunol 24: 51-57.
101. Sobhian B., Laguette N, Yatim A, Nakamura M, Levy Y, Kiernan R, Benkirane M. 2010. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol Cell 38: 439-451.
102. Su I.H., Basavaraj A, Krutchinsky AN, Hobert O, Ullrich A, Chait BT, Tarakhovsky A. 2003. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 4: 124-131.
103. Su I.H., Dobenecker MW, Dickinson E, Oser M, Basavaraj A, Marqueron R., Viale A, Reinberg D, Wulfing C, Tarakhovsky A. 2005. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121: 425-436.
104. Vainchenker W., Delhommeau F, Constantinescu SN, Bernard OA. 2011. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118: 1723-1735.
105. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ. 2001. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97: 3896-3901.
106. Varambally S., Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C., Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
107. Velichutina I., Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, Elemento O. 2010. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116: 5247-5255.
108. Vesely M.D., Kershaw MH, Schreiber RD, Smyth MJ. 2011. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235-271.
109. Wei G., Wei L, Zhu J, Zang C, Hu-Li J, Yao Z, Cui K, Kanno Y, Roh T.Y., Watford WT, et al. 2009. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 30: 155-167.
110. Witte V., Laffert B, Rosorius O, Lischka P, Blume K, Galler G, Stilper A., Willbold D, D'Aloja P, Sixt M, et al. 2004. HIV-1 Nef mimics an integrin receptor signal that recruits the polycomb group protein Eed to the plasma membrane. Mol Cell 13: 179-190.
111. Xu K., Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, et al. 2012. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338: 1465-1469.
112. Yap D.B., Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin R.D., Mungall AJ, Meissner B, Boyle M, et al. 2011. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117: 2451-2459.
113. You J., Croyle JL, Nishimura A, Ozato K, Howley PM. 2004. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 117: 349-360.
114. Zak D.E., Aderem A. 2009. Systems biology of innate immunity. Immunol Rev 227: 264-282.
115. Zeng L., ZhouMM. 2002. Bromodomain: An acetyl-lysine binding domain. FEBS Lett 513: 124-128.
116. Zhou Q., Li T, Price DH. 2012. RNA polymerase II elongation control. Annu Rev Biochem 81: 119-143.
117. Zuber J., Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D., Qi J, Blatt K, Wunderlich M, et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.